|Day Low/High||9.72 / 10.59|
|52 Wk Low/High||2.09 / 33.79|
Let's review the charts and indicators.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
The price action is very bullish right now so a fresh look is warranted.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
As State economies begin the slow process of reopening, the Fed is there to support market function. Facebook's latest e-commerce foray has investors cheering.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
Current owners of the small biotech company's shares should continue to hold them based on its charts but should put in a stop, too.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
This biotech is one of two companies in human trials for a vaccine for Covid-19.
A look at some names that Robinhood brokerage CEO Tenev tells us young people are buying.
I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.
The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.
There are small vaccine and testing companies that see their shares spike when a new virus hits, but whether those gains will last is questionable.
I'll stick to the three-pronged approach... the Rebound group, the Virus group, and the Revenue group.
These sort of panics can be turn out to be lucrative opportunities for investors.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.
The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
Identifying this week's bullish and bearish reversal patterns.
These four biotech stocks have been moving on some interesting news and clinical results.
I am happy to be standing in for Doug Kass this Friday morning as we end what has been a somewhat volatile week for trading. The big banks such as Citicorp and Wells Fargo are due to report before the bell this morning as we get further along into t...
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
Looking for a breakout on banks and bonds.